Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Leukemia

Volumn 23, Issue 1, 2009, Pages 3-9

  Kyle, R A ^a   Rajkumar, S V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ANEMIA; BONE DISEASE; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CELL ASSAY; CELL LABELING; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; CYTOGENETICS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG RESEARCH; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; INTERMETHOD COMPARISON; LABORATORY TEST; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PLASMA CELL; PLASMACYTOMA; POEMS SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; STANDARDIZATION; SURVIVAL TIME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 58249097191     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.291     Document Type: Review

References (30)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc 2003; 78: 21-33.
2. Snozek CLH, Katzmann JA, Kyle RA, Dispenzieri A, Larson D, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: Proposed incorporation into the International Staging System. Leukemia 2008; 22: 1933-1937.
3. Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS). Blood 2005; 106: 812-817.
4. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
5. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979-1983.
6. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
7. Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment.[see comment]. Mayo Clinic Proc 2005; 80: 1371-1382.
8. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003; 102: 3759-3764.
9. Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P et al Prognostic validation of the international classification of immunoglobulin M gammopathies: A survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance? Clin Cancer Res 2005; 11: 1786-1790.
10. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003; 30: 169-171.
11. Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol 2005; 23: 4662-4668.
12. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110-115.
13. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000; 96: 2037-2044.
14. Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. Hematol Oncol Clin North Am 1999; 13: 1249-1257.
15. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: Diagnosis and treatment. Mayo Clin Proc 2006; 81: 693-703.
16. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR et al. POEMS syndrome: Definitions and long-term outcome. Blood 2003; 101: 2496-2506.
17. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36 842-854.
18. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 1983; 55: 439-447.
19. Greipp PR, San Miguel JF, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International Staging System for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
20. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
21. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, Groupe Francais de Cytogenetique H. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
22. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
23. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E et al Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
24. Rajkumar SV, Kyle RA. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371-1382.
25. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
26. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
27. Greipp PR, Lust JA, WM OF, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]. Blood 1993; 81: 3382-3387.
28. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
29. Durie BGM, Harousseau J-L, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
30. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231-239.